Bioatla Non Operating Income Net Other from 2010 to 2026
| BCAB Stock | USD 0.14 0.01 6.67% |
Non Operating Income Net Other | First Reported 2010-12-31 | Previous Quarter 1.5 M | Current Value 1.3 M | Quarterly Volatility 87.6 K |
Check Bioatla financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bioatla's main balance sheet or income statement drivers, such as Net Interest Income of 4.1 M, Interest Income of 4.1 M or Depreciation And Amortization of 1.2 M, as well as many indicators such as Price To Sales Ratio of 2.23, Dividend Yield of 0.0 or PTB Ratio of 1.9. Bioatla financial statements analysis is a perfect complement when working with Bioatla Valuation or Volatility modules.
Bioatla | Non Operating Income Net Other | Build AI portfolio with Bioatla Stock |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Bioatla offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bioatla's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bioatla Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bioatla Stock:Check out the analysis of Bioatla Correlation against competitors. For information on how to trade Bioatla Stock refer to our How to Trade Bioatla Stock guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bioatla. Projected growth potential of Bioatla fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Bioatla assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Bioatla is measured differently than its book value, which is the value of Bioatla that is recorded on the company's balance sheet. Investors also form their own opinion of Bioatla's value that differs from its market value or its book value, called intrinsic value, which is Bioatla's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bioatla's market value can be influenced by many factors that don't directly affect Bioatla's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Bioatla's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Bioatla should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Bioatla's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.